Antipsychotic drugs classified by their effects on the release of dopamine and noradrenaline in the prefrontal cortex and striatum

Andersson, 1995, Ritanserin potentiates the stimulatory effects of raclopride on neuronal activity and dopamine release selectively in the mesolimbic dopaminergic system, Naunyn-Schmiedeberg's Arch. Pharmacol., 352, 374, 10.1007/BF00172774 Arborelius, 1996, Naunyn-Schmiedeberg's Arch. Pharmacol., 353, 630, 10.1007/BF00167182 Arnt, 1998, Do novel antipsychotics have similar pharmacological characteristics? A review of the evidence, Neuropsychopharmacology, 18, 10, 10.1016/S0893-133X(97)00112-7 Bunney, 1973, Dopaminergic neurons: effect of antipsychotic drugs and amphetamine on single cell activity, J. Pharmacol. Exp. Ther., 185, 560 Carlsson, 1963, Effect of chlorpromazine or haloperidol on formation of 3-methoxytyramine and normetanephrine in mouse brain, Acta Pharmacol., 20, 140, 10.1111/j.1600-0773.1963.tb01730.x Danion, 1999, Improvement of schizophrenic patients with primary negative symptoms treated with amisulpride. Amisulpride Group, Am. J. Psychiatry, 156, 610, 10.1176/ajp.156.4.610 De Boer, 1990, The effect of acetylcholinesterase inhibition on the release of acetylcholine from the striatum in vivo: interaction with autoreceptor responses, Neurosci. Lett., 116, 357, 10.1016/0304-3940(90)90101-E Di Chiara, 1977, Haloperidol increases and apomorphine decreases striatal dopamine metabolism after destruction of striatal dopamine-sensitive adenylate-cyclase by kainic acid, Brain Res., 130, 374, 10.1016/0006-8993(77)90286-4 Dringenberg, 1998, Increased levels of extracellular dopamine in neostriatum and nucleus accumbens after histamine H1 receptor blockade, Naunyn-Schmiedeberg's Arch. Pharmacol., 358, 423, 10.1007/PL00005274 Gobert, 1999, Serotonin (5-HT)2A receptor activation enhances dialysate levels of dopamine and noradrenaline, but not 5-HT, in the frontal cortex of freely moving rats, Neuropharmacology, 38, 315, 10.1016/S0028-3908(98)00188-9 Hertel, 1996, Risperidone: regional effects in vivo on release and metabolism of dopamine and serotonin in the rat brain, Psychopharmacology, 124, 74, 10.1007/BF02245607 Hertel, 1999, Enhanced cortical dopamine output and antipsychotic-like effects of raclopride by alpha2 adrenoceptor blockade, Science, 286, 105, 10.1126/science.286.5437.105 Kuroki, 1999, Effects of antipsychotic drugs on extracellular dopamine levels in rat medial prefrontal cortex and nucleus accumbens, J. Pharmacol. Exp. Ther., 288, 774 Lewander, 1994, Overcoming the neuroleptic-induced deficit syndrome: clinical observations with remoxipride, Acta Psychiatr. Scand., Suppl., 380, 64, 10.1111/j.1600-0447.1994.tb05835.x Leysen, 1994, Risperidone: a novel antipsychotic with balanced serotonin–dopamine antagonism, receptor occupancy profile, and pharmacologic activity, J. Clin. Psychiatry, 55, 5 Li, 1998, Olanzapine increases in vivo dopamine and norepinephrine release in rat prefrontal cortex, nucleus accumbens and striatum, Psychopharmacology, 136, 153, 10.1007/s002130050551 Marcus, 1996, Differential action of typical and atypical antipsychotic drugs on dopamine release in the core and the shell of the nucleus accumbens, Eur. Neuropsychopharmacol., 6, 29, 10.1016/0924-977X(95)00056-U Melis, 1999, Clozapine potently stimulates mesocortical dopamine neurons, Eur. J. Pharmacol., 366, R11, 10.1016/S0014-2999(98)00934-0 Meltzer, 1995, Role of serotonin in the action of atypical antipsychotic drugs, Clin. Neurosci., 64 Moghaddam, 1990, Acute effects of typical and atypical antipsychotic drugs on the release of dopamine from prefrontal cortex, nucleus accumbens, and striatum of the rat: an in vivo microdialysis study, J. Neurochem., 54, 1755, 10.1111/j.1471-4159.1990.tb01230.x Nomikos, 1994, Systemic administration of amperozide, a new atypical antipsychotic drug, preferentially increases dopamine release in the rat medial prefrontal cortex, Psychopharmacology, 115, 147, 10.1007/BF02244765 Paxinos, 1982 Pehek, 1993, The atypical antipsychotic drug amperozide enhances rat cortical and striatal dopamine efflux, Eur. J. Pharmacol., 240, 107, 10.1016/0014-2999(93)90555-V Perrault, 1997, Psychopharmacological profile of amisulpride: an antipsychotic drug with presynaptic D2/D3 dopamine receptor antagonist activity and limbic selectivity, J. Pharmacol. Exp. Ther., 280, 73 Peuskens, 1999, Amisulpride vs. rispiridone in the treatment of acute exacerbations of schizophrenia. Amisulpride study group, Psychiatry Res., 88, 107, 10.1016/S0165-1781(99)00075-X Ramaekers, 1999, Psychommotor, cognitive, extrapyramidal, and affective functions of healthy volunteers during treatment with atypical (amisulpride) and a classic (haloperidol) antipsychotic, J. Clin. Psychopharmacol., 19, 209, 10.1097/00004714-199906000-00003 Rollema, 1997, Clozapine increases dopamine release in prefrontal cortex by 5-HT1A receptor activation, Eur. J. Pharmacol., 338, R3, 10.1016/S0014-2999(97)81951-6 Roth, 1994, Binding of typical and atypical antipsychotic agents to 5-hydroxytryptamine-6 and 5-hydroxytryptamine-7 receptors, J. Pharmacol. Exp. Ther., 268, 1403 Routledge, 1993, Neurochemical profile of the selective and silent 5-HT1A receptor antagonists WAY100135: an in vivo microdialysis study, Eur. J. Pharmacol., 239, 195, 10.1016/0014-2999(93)90994-S Schmidt, 1995, The selective 5-HT2A receptor antagonist, MDL 100,907, increases dopamine efflux in the prefrontal cortex of the rat, Eur. J. Pharmacol., 273, 273, 10.1016/0014-2999(94)00698-7 Schotte, 1996, Risperidone compared with new and reference antipsychotic drugs: in vitro and in vivo receptor binding, Psychopharmacology, 124, 57, 10.1007/BF02245606 Stockmeier, 1993, Characterization of typical and atypical antipsychotic drugs based on in vivo occupancy of serotonin2 and dopamine2 receptors, J. Pharmacol. Exp. Ther., 266, 1374 Volavka, 1996, Effect of varying haloperidol plasma levels on negative symptoms in schizophrenia and schizoaffective disorder, Psychopharmacol. Bull., 32, 75 Volonté, 1997, BMG80, a novel potential antipsychotic drug: evidence for multireceptor actions and preferential release of dopamine in prefrontal cortex, J. Neurochem., 69, 182, 10.1046/j.1471-4159.1997.69010182.x Weinberger, 1995, Cortical maldevelopment, antipsychotic drugs, and schizophrenia: a search for common ground, Schizophr. Res., 16, 87, 10.1016/0920-9964(95)00013-C Westerink, 1989, On the mechanism of neuroleptic induced increase in striatal dopamine release: brain dialysis provides direct evidence for mediation by autoreceptors localized on nerve terminals, Neurosci. Lett., 99, 97, 10.1016/0304-3940(89)90289-9 Westerink, 1998, Antipsychotic drugs induce similar effects on the release of dopamine and noradrenaline in the medial prefrontal cortex of the rat brain, Eur. J. Pharmacol., 361, 27, 10.1016/S0014-2999(98)00711-0